Home / Intelligence / Case Studies / Early Payer Guidance Across Four Inflammatory Disease Areas
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.
Geographic Scope: 
Client Situation
The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.
Trinity’s Solution
Trinity conducted comprehensive secondary research in the following areas:
- Disease background including diagnosis, prognosis, epidemiology and unmet needs
- Current and future paradigm including lines of therapies and standard of care
- Pipeline analysis including key therapies in development and future treatment gamechangers
- Pricing and access landscape including pricing analysis, health technology assessment (HTA) outcomes and access status
Deliverables
Four disease-specific early payer guidance reports powered by comprehensive secondary research efforts into disease background, current and future treatment paradigm, pipeline analysis and pricing and access landscape.
Project Outcomes & Impact
Trinity’s comprehensive secondary research and landscape analyses helped the client to make early-stage decisions across therapeutic areas of interest from a future business development perspective.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More